There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Unicycive Therapeutics (UNCY – Research Report), Janux Therapeutics Inc (JANX – Research Report) and Medtronic (MDT – Research Report) with bullish sentiments.
Unicycive Therapeutics (UNCY)
H.C. Wainwright analyst Ed Arce maintained a Buy rating on Unicycive Therapeutics today and set a price target of $7.00. The company’s shares closed last Tuesday at $1.28.
According to TipRanks.com, Arce is a 5-star analyst with an average return of
Unicycive Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $5.00.
See today’s best-performing stocks on TipRanks >>
Janux Therapeutics Inc (JANX)
In a report released yesterday, Geoff Meacham from Bank of America Securities reiterated a Buy rating on Janux Therapeutics Inc, with a price target of $25.00. The company’s shares closed last Tuesday at $12.49.
According to TipRanks.com, Meacham is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Janux Therapeutics Inc with a $28.00 average price target, implying a 131.0% upside from current levels. In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $35.00 price target.
Medtronic (MDT)
In a report released yesterday, Travis Steed from Bank of America Securities maintained a Buy rating on Medtronic, with a price target of $100.00. The company’s shares closed last Tuesday at $86.60.
According to TipRanks.com, Steed is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Medtronic with a $97.94 average price target, a 13.7% upside from current levels. In a report issued on July 6, Evercore ISI also maintained a Buy rating on the stock with a $102.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on UNCY:
- Unicycive Therapeutics Announces Publication of Positive Comparison of Oxylanthanum Carbonate to Commercially Available Phosphate Binders in the American Journal of Nephrology
- Unicycive Therapeutics files to sell 111.02M shares of common stock for holders
- Unicycive Therapeutics price target lowered to $4 from $6 at Maxim
- Unicycive selloff brings ‘excellent entry point,’ says H.C. Wainwright
- Unicycive Therapeutics Provides Regulatory Update on Lanthanum Dioxycarbonate Program
